重组人血管内皮抑制素在晚期前列腺癌患者中的应用  

Applicable exploration of recombinant human endostatin on patientswith advanced prostatic carcinoma

作　　者：黄国福[1] 冷晓玲[2] 

机构地区：[1]新疆医科大学第五附属医院放化疗科,新疆乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院超声科,新疆乌鲁木齐830011

出　　处：《实用临床医药杂志》2014年第15期70-72,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11321291)

摘　　要：目的探讨长期联用重组人血管内皮抑制素治疗晚期前列腺癌的临床疗效。方法分析28例晚期前列腺癌病例,实验组18例,对照组10例,对照组采用内分泌治疗及放射治疗,实验组在对照组的治疗基础上加用重组人血管内皮抑制素,检查血清总前列腺特异性抗原(TPSA)、游离前列腺特异性抗原(FPSA)水平,观察不良反应发生情况。结果实验组及对照组治疗后FPSA、TPSA均显著降低(P<0.01)。治疗3、6、12、28个月时实验组患者的FPSA、TPSA值均显著低于对照组(P<0.01)。FPSA及TPSA曲线图显示实验组各时间点的数值均低于对照组。实验组骨髓抑制Ⅱ度和Ⅲ度患者总例数显著高于对照组(P<0.01),2组患者凝血功能、胃肠道反应无显著差异(P>0.05)。肝功能检查见谷草转氨酶(AST)或谷丙转氨酶(ALT)水平轻度升高,经保肝治疗后好转,2组比较无显著差异(P>0.05)。结论联合重组人血管内皮抑制素治疗晚期前列腺癌优于单用内分泌及放射治疗,副作用以骨髓抑制为主。Objective To explore the clinical efficacy of long- term application of recombinant human endostatin on patients with advanced prostatic carcinoma. Methods Twenty- eight patients with prostatic carcinoma were divided into control group（ 10 cases） treated with endocrine therapy and radiotherapy and experimental group（ 18 cases） added with recombinant human endostatin.Serum total prostate specific antigen（ TPSA） and free prostate specific antigen（ FPSA） levels were detected and adverse responses were observed. Results FPSA and TPSA levels decreased evidently in both groups after treatment（ P〈 0. 01）,and were obviously lower in experimental group than in control group 3,6,12 and 28 months after treatment（ P〈 0. 01）. Additionally,their curve charts showed that their levels in each time point was lower in experimental group than in control group.The number of patients with myelosuppression in degrees Ⅱ and Ⅲ was markedly higher in experimental group than in control group（ P〈 0. 01）,but there were no significant differences in those with coagulation disorders and gastrointestinal responses（ P〈 0. 05）. Liver function examination indicated that aspartate transaminase（ AST） and alanine transaminase（ ALT） had slight increase and were improved after liver- protection therapies,which had no significant differences between two groups（ P〉0. 05）. Conclusion Combined application with recombinant human endostatin has better clinical efficacy than single utilization of endocrine therapy and radiotherapy on patients with advanced prostatic carcinoma,in which the myolesuppression is the primary adverse response.

关 键 词：重组人血管内皮抑制素 前列腺癌 血清总前列腺特异性抗原 游离前列腺特异性抗原 

分 类 号：R737.25[医药卫生—肿瘤]